RecruitingPhase 2NCT05027633
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
Studying Squamous cell carcinoma of the nasal cavity and paranasal sinuses
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- M.D. Anderson Cancer Center
- Principal Investigator
- Renata Ferrarotto, MDM.D. Anderson Cancer Center
- Intervention
- Pembrolizumab(drug)
- Enrollment
- 35 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2028
Study locations (1)
- M D Anderson Cancer Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05027633 on ClinicalTrials.govOther trials for Squamous cell carcinoma of the nasal cavity and paranasal sinuses
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT05614375Endoscopic Surgery in the Treatment of Soft Tissue Sarcoma in Nasal and Paranasal SinusEye & ENT Hospital of Fudan University
- ACTIVE NOT RECRUITINGPHASE2NCT00707473Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus CancerM.D. Anderson Cancer Center
See all trials for Squamous cell carcinoma of the nasal cavity and paranasal sinuses →